Manidipine 2HClCAS# 89226-75-5 |
- Zileuton
Catalog No.:BCC2515
CAS No.:111406-87-2
- Zileuton sodium
Catalog No.:BCC4216
CAS No.:118569-21-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 89226-75-5 | SDF | Download SDF |
| PubChem ID | 150762 | Appearance | Powder |
| Formula | C35H40Cl2N4O6 | M.Wt | 683.62 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 50 mg/mL (73.14 mM; Need ultrasonic) | ||
| Chemical Name | 5-O-[2-(4-benzhydrylpiperazin-1-yl)ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;dihydrochloride | ||
| SMILES | CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC.Cl.Cl | ||
| Standard InChIKey | JINNGBXKBDUGQT-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C35H38N4O6.2ClH/c1-24-30(34(40)44-3)32(28-15-10-16-29(23-28)39(42)43)31(25(2)36-24)35(41)45-22-21-37-17-19-38(20-18-37)33(26-11-6-4-7-12-26)27-13-8-5-9-14-27;;/h4-16,23,32-33,36H,17-22H2,1-3H3;2*1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Manidipine 2HCl Dilution Calculator
Manidipine 2HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.4628 mL | 7.314 mL | 14.628 mL | 29.256 mL | 36.57 mL |
| 5 mM | 0.2926 mL | 1.4628 mL | 2.9256 mL | 5.8512 mL | 7.314 mL |
| 10 mM | 0.1463 mL | 0.7314 mL | 1.4628 mL | 2.9256 mL | 3.657 mL |
| 50 mM | 0.0293 mL | 0.1463 mL | 0.2926 mL | 0.5851 mL | 0.7314 mL |
| 100 mM | 0.0146 mL | 0.0731 mL | 0.1463 mL | 0.2926 mL | 0.3657 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Manidipine dihydrochloride is a dihydropyridine compound and a calcium channel blocker for Ca2+ current with IC50 of 2.6 nM.
- Manidipine
Catalog No.:BCC4404
CAS No.:89226-50-6
- LY2334737
Catalog No.:BCC4060
CAS No.:892128-60-8
- Mulberrofuran H
Catalog No.:BCN3371
CAS No.:89199-99-5
- Fraxiresinol 1-O-glucoside
Catalog No.:BCN4439
CAS No.:89199-94-0
- Efaroxan hydrochloride
Catalog No.:BCC6797
CAS No.:89197-00-2
- 15,16-Dihydrotanshindiol C
Catalog No.:BCN3214
CAS No.:891854-96-9
- 1,2-Didehydrocryptotanshinone
Catalog No.:BCN3122
CAS No.:891854-92-5
- 15,16-Dihydrotanshindiol B
Catalog No.:BCN3213
CAS No.:891854-86-7
- SCH900776 S-isomer
Catalog No.:BCC1936
CAS No.:891494-64-7
- MK-8776 (SCH-900776)
Catalog No.:BCC3817
CAS No.:891494-63-6
- Betulin caffeate
Catalog No.:BCN4438
CAS No.:89130-86-9
- Odoratisol A
Catalog No.:BCN7813
CAS No.:891182-93-7
- AZD 3988
Catalog No.:BCC5621
CAS No.:892489-52-0
- 2-(Chloromethyl)-4-(4-nitrophenyl)-1,3-thiazole
Catalog No.:BCC8372
CAS No.:89250-26-0
- MF63
Catalog No.:BCC1744
CAS No.:892549-43-8
- 2,4-Dihydroxy-3-nitropyridine
Catalog No.:BCC8499
CAS No.:89282-12-2
- 3,4-O,O-Methylene-(+)-catechin
Catalog No.:BCN7962
CAS No.:89329-14-6
- ICI 174,864
Catalog No.:BCC5675
CAS No.:89352-67-0
- Chiisanoside
Catalog No.:BCN2712
CAS No.:89354-01-8
- Riligustilide
Catalog No.:BCC9136
CAS No.:89354-45-0
- PF 945863
Catalog No.:BCC6172
CAS No.:893556-85-9
- Imidapril HCl
Catalog No.:BCC3792
CAS No.:89396-94-1
- VU 0240551
Catalog No.:BCC5424
CAS No.:893990-34-6
- LDN 212320
Catalog No.:BCC6361
CAS No.:894002-50-7
[Beneficial effects of the combination of idebenone and manidipine 2HCl on neurological deficits and histological changes following cerebrovascular lesions in stroke-prone spontaneously hypertensive rats].[Pubmed:8566909]
Nihon Yakurigaku Zasshi. 1995 Nov;106(5):327-37.
We investigated the effects of the combination of idebenone, an energy metabolism enhancer, and Manidipine 2HCl, a dihydropyridine-derivative calcium antagonist, on neurological deficits and histological changes in the brain and kidneys of stroke-prone spontaneously hypertensive rats (SHRSP) with cerebrovascular lesions (stroke). The SHRSP were kept on a 1% NaCl solution as their drinking water to synchronize the onset of stroke. After the onset of stroke symptoms, the salt solution was replaced with tap water. On the day following the onset of stroke, idebenone (50 mg/kg), Manidipine 2HCl (2 mg/kg) or a combination of idebenone (50 mg/kg) and Manidipine 2HCl (2 mg/kg) was administered orally once a day for 3 weeks. In the combination group and Manidipine 2HCl-treated group, the neurological deficits after the onset of stroke were ameliorated during the entire experimentalperiod. Especially, the combination significantly decreased the number of days with severe neurological deficits as compared to the control group. The combination and Manidipine 2HCl significantly recovered the decrease in body weight and ameliorated the increase of brain weight, which was mainly caused by edema, significantly as compared to the control group. Manidipine 2HCl ameliorated the histological changes in the brain. In the combination group, the histological changes in both the brain and the kidneys were ameliorated. In conclusion, the combination of idebenone and Manidipine 2HCl significantly ameliorated the neurological deficits and the histological changes in the brain and the kidney of SHRSP with stroke as compared to each individual treatment. We concluded that Manidipine 2HCl enhances the therapeutic effect of idebenone in the treatment of cerebrovascular diseases.
